Abstract
Background
The aim of this study was to investigate the quantification performance of a 360° CZT camera for 177Lu-based treatment monitoring.
Methods
Three phantoms with known 177Lu activity concentrations were acquired: (1) a uniform cylindrical phantom for calibration, (2) a NEMA IEC body phantom for analysis of different-sized spheres to optimise quantification parameters and (3) a phantom containing two large vials simulating organs at risk for tests. Four sets of reconstruction parameters were tested: (1) Scatter, (2) Scatter and Point Spread Function Recovery (PSFR), (3) PSFR only and (4) Penalised likelihood option and Scatter, varying the number of updates (iterations × subsets) with CT-based attenuation correction only. For each, activity concentration (ARC) and contrast recovery coefficients (CRC) were estimated as well as root mean square. Visualisation and quantification parameters were applied to reconstructed patient image data.
Results
Optimised quantification parameters were determined to be: CT-based attenuation correction, scatter correction, 12 iterations, 8 subsets and no filter. ARC, CRC and RMS results were dependant on the methodology used for calculations. Two different reconstruction parameters were recommended for visualisation and for quantification. 3D whole-body SPECT images were acquired and reconstructed for 177Lu-PSMA patients in 2–3 times faster than the time taken for a conventional gamma camera.
Conclusion
Quantification of whole-body 3D images of patients treated with 177Lu-PSMA is feasible and an optimised set of parameters has been determined. This camera greatly reduces procedure time for whole-body SPECT.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Badel, Jean-Noël 1 ; Giraudet, Anne-Laure 2 ; Kryza, David 3 ; Mognetti, Thomas 2 ; Baudier, Thomas 1 ; Rida, Hanan 4 ; Dieudonné, Arnaud 4 ; Sarrut, David 1 1 Centre de lutte contre le cancer Léon Bérard, Lyon, France (GRID:grid.418116.b) (ISNI:0000 0001 0200 3174); CREATIS, CNRS UMR 5220, INSERM U 1044, Université de Lyon, INSA-Lyon, Université Lyon 1, Lyon, France (GRID:grid.15399.37) (ISNI:0000 0004 1765 5089)
2 Centre de lutte contre le cancer Léon Bérard, Lyon, France (GRID:grid.418116.b) (ISNI:0000 0001 0200 3174)
3 Centre de lutte contre le cancer Léon Bérard, Lyon, France (GRID:grid.418116.b) (ISNI:0000 0001 0200 3174); Hospices Civils de Lyon, Université de Lyon, Université Claude Bernard Lyon 1, LAGEPP UMR 5007 CNRS, Lyon, France (GRID:grid.413852.9) (ISNI:0000 0001 2163 3825)
4 Département de médecine nucléaire, Centre Henri Becquerel, Rouen, France (GRID:grid.15399.37) (ISNI:0000 0000 9653 5464)




